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Department of Medicine, Ottawa General Hospital, University of Ottawa, Ottawa, Ontario, Canada 
Our objective was to determine whether methotrexate is an effective steroid-sparing agent for patients with severe 
asthma. Published reports of controlled trials assessing the use of methotrexate in asthma were identified by a search 
of the MEDLINE, EMBASE, CINAHL, Biological Abstracts on CD, and Current Contents databases. Bibliogra- 
phies from identified studies and from review articles were manually searched. Published and unpublished reports in 
any language were identified and assessed for inclusion in the meta-analysis. We selected randomized, double-blind, 
placebo-controlled trials in which low-dose methotrexate was administered to corticosteroid-dependent asthmatics, 
and oral steroids were subsequently tapered according to the patients’ clinical status. 
Data were extracted independently by two reviewers. For all eligible trials, the mean reduction in oral 
corticosteroid dose, the mean change in FEV,, and the standard deviations, were calculated for the treatment and 
control groups. Data concerning side-effects of therapy were also extracted. Data from 12 studies, reporting on a 
total of 250 patients, were pooled using a weighted average method, with weights proportional to the inverse of the 
variance of the treatment effect. Compared to placebo, the use of methotrexate was associated with a pooled 6.0”/) 
improvement in FEV, (95% CI, 1.0-l 1%) and an 18.2”/0 reduction in oral steroid use (95% CI, 11.7-24.7%). This 
corresponded to a 3.3 mg day - ’ greater reduction in oral steroid use for patients taking methotrexate than for those 
taking placebo (95% CI, 2.1-1.4 mg day ~ ‘). Gastrointestinal complications and transient increases in liver enzymes 
were more common in patients randomized to methotrexate. Three potentially life-threatening side-effects (two 
pneumonias and one liver dysfunction) occurred in 1.59 patients randomized to methotrexate rs. none in those 
patients on placebo. It was concluded that methotrexate allowed a modest reduction in oral corticosteroid compared 
to patients receiving placebo. The benefit is relatively small, however, and should be balanced against the potential 
for side-effects associated with the use of ‘methotrexate 
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Introduction 
Asthma is an inflammatory disorder of the airways Charac- 
terized by variable airflow obstruction. For most asthmat- 
ics, airway inflammation and asthma symptoms are 
adequately controlled with inhaled corticosteroids and 
bronchodilators, medications which are associated with 
minimal systemic side-effects. However, a subgroup of 
patients with severe asthma do not achieve adequate con- 
trol with inhaled medications, and instead require pro- 
longed courses of oral corticosteroids to control their 
disease. These corticosteroid-dependent patients are often 
subject to debilitating complications associated with the 
long-term use of systemic prednisone therapy (1). 
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The need for alternatives to long-term steroid therapy 
has prompted investigators to search for other agents which 
might help to control severe asthma and enable patients to 
reduce their reliance on systemic steroids (2). In 1986 a case 
report was published, describing a steroid-dependent asth- 
matic who was weaned off oral steroids after methotrexate 
was coincidentally prescribed for psoriasis (3). Since this 
initial case report, numerous studies have been published in 
the world literature evaluating the use of methotrexate in 
steroid-dependent asthma (423). Many of the published 
trials have been small and lacking power, and different 
studies have often yielded conflicting results. Most narra- 
tive reviews of past clinical trials have provided equivocal 
conclusions as to whether the drug is effective and safe in 
this population (24,25). 
We undertook a quantitative analysis of all randomized, 
placebo-controlled trials in which methotrexate was used 
to treat steroid-dependent asthma, in order to determine 
methotrexate’s efficacy, and to estimate the magnitude of its 
corticosteroid sparing effect in patients with severe asthma. 
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Methods ASSESSMENT OF TRIAL QUALITY 
We attempted to identify and include all randomized, 
placebo-controlled trials assessing the effects of methotrex- 
ate in steroid-dependent asthma. Since the primary out- 
come variable of all the trials assessed was a reduction in 
oral corticosteroid use, and since reduction in steroid use 
was dependent on the investigators who controlled the 
steroid tapering process, only those trials which were 
placebo-controlled and double-blinded were considered free 
of potential bias, and therefore only these trials were 
included in the meta-analysis. 
LITERATURE SEARCH 
We identified potential trials published in any language 
by searching MEDLINE (1966January 1998), EMBASE 
(1980-1997), CINAHL (Cumulated Index to Nursing and 
Allied Health 1982-1997), Biological Abstracts on CD 
(1990-1997), and Current Contents (1996January 1998). 
For this search we used the following items: (exp asthma, 
asthma tw., bronchial hyperreactivity tw.) and (exp meth- 
otrexate, methotrexate tw, methotrexate rn). No restric- 
tions for the language of publication or the study design 
were made. 
We obtained a list of published and unpublished trials 
from the pharmaceutical company which manufactures 
methotrexate in Canada, Wyeth-Ayerst. The reference lists 
of all relevant trials and review articles obtained via the 
previous searching strategies were manually searched. In 
addition, we contacted investigators of the studies included 
in the meta-analysis in order to locate any unpublished 
material, and to obtain any incomplete data that was 
missing from the published papers. 
Two reviewers (S.D.A. and R.E.D.), independently 
assessed and selected randomized controlled trials for inclu- 
sion in the meta-analysis. To be included in the meta- 
analysis the trial had to satisfy the following three inclusion 
criteria: 
(1) Target population -We accepted trials which studied 
adults or children with documented asthma (defined as 
reversible airflow obstruction with at least a 15% improve- 
ment in forced expiratory volume in 1 s (FEV,) either 
spontaneously or after bronchodilator therapy), who were 
dependent on daily oral corticosteroid therapy (at least 
Smgday-’ of prednisone or equivalent), before entry into 
the trial. 
(2) Intervention -The treatment protocols consisted of low- 
dose methotrexate (7.5-30 mg) administered once weekly, 
orally or intramuscularly. 
(3) Study design-The studies had to be randomized, 
placebo-controlled, double-blind trials for inclusion into 
the meta-analysis. Parallel and cross-over studies were 
accepted. In order to be eligible for the meta-analysis, the 
patients taking placebo or methotrexate had to have been 
placed on identical steroid-tapering regimens, and the 
reduction in oral steroid requirements of each group had to 
have been reported. 
Those studies meeting the inclusion criteria were then 
assessed by using a validated three-item scale (26) designed 
to measure trial quality. The scale assessed the quality of 
randomization, double-blinding, and inclusion of data for 
dropouts and withdrawals. The scale scores range from 0 to 
5, with a score of 5 indicating superior quality of reporting. 
In cases where there was disagreement between the two 
reviewers, a consensus quality score was arrived at. 
DATA COLLECTION 
Two reviewers independently abstracted data from ident- 
ified studies regarding the trial design, patient characteris- 
tics, dosages and treatment periods. The mean daily oral 
steroid dose at baseline for the treatment and control 
groups and the standard deviations or standard error for 
steroid doses were collected. These were compared to the 
mean daily steroid dose used by the treatment and control 
groups at the end of the trial period. Similar data was 
collected for FEV,. In cases where data was available, 
results for individual patient steroid use within each study 
was recorded as well. 
STATISTICAL ANALYSIS 
To standardize the data and determine the relative reduc- 
tion in oral steroid requirement for each group, the percent- 
age change from baseline in mean daily oral steroid dose for 
each group was calculated as 100 x (final value-baseline 
value)/baseline value. For each trial, the net steroid-sparing 
effect of methotrexate vs placebo was calculated as the 
difference in the percent change in oral steroid use from 
baseline in the methotrexate group minus the difference 
observed in the placebo group. Similar calculations were 
used to assess the percentage change in FEV,. 
Data on the net steroid-sparing effect of the intervention 
vs placebo was pooled using weighted averages, with 
weights equal to the inverse of the variance of the observed 
effect (27) (see Appendix). This allowed us to calculate an 
overall weighted mean difference as an estimate of the 
effectiveness of methotrexate. For studies which did not 
report the variance measures needed to calculate weights 
for the pooled analysis, we used a sample-size based 
weighted average of the reported variances. 
Individual patient data was collected when it was avail- 
able, from publications or correspondence with authors, to 
determine the proportion of patients in the treatment and 
control groups who achieved a 220% reduction in oral 
steroid use. A pooled odds ratio was estimated from this 
data using the DerSimonian and Laird random-effects 
model (28). Between-trial heterogeneity was evaluated using 
Cochran’s Q-test. Inter-reviewer agreement in the selection 
of relevant studies and the assessment of methodological 
quality was calculated using the weighted kappa statistic. 
We identified, a priori, three potential sources of hetero- 
geneity among trial findings. We postulated that the design 
of the trial might affect its findings, specifically that cross- 
over trials might show a more significant treatment effect 
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TABLE 1. Randomized, placebo-controlled studies of methotrexate in asthma 
Study 
No. of Mean entry Duration 
No. of patients prednisone MTX of treatment Trial 
randomized completing Study dose mg day - ’ dosage with MTX quality 
patients study design ( f SD) mg week-‘* (weeks) score 
Stewart, 1994 (4) 24 21 Cross-over 21.0 Lt 7.9 1.5 12 415 
Erzurum, 1991 (5) 19 17 Parallel 19.7 Z!Z 4.6 15 (IM) 13 415 
Mullarkey, 1988 (6) 14 13 Cross-over 24.8 f 15.3 15 12 415 
Dyer, 1991 (7) 12 10 Cross-over 13.1 f 5.3 15 12 415 
Hedman, 1996 (14) 13 12 Cross-over 10.9 & 8.4 15 12 415 
Coffey, 1994 (15) 14 11 Cross-over 30.8 zk 15.6 15 12 315 
Ogirala, 1995 (8)t 15 13 Parallel 6.6 * 7.7 15 26 415 
Shiner, 1990 (9) 69 60 Parallel 14.0 f 5.5 15 24 415 
Taylor, 1993 (10) 11 9 Cross-over 16.1 f 7.5 15 24 415 
Kanzow, 1995 (11) 24 21 Parallel 27.8 f 11.5 15 16 415 
Trigg, 1993 (12) 18 12 Cross-over 17.7 f 8.4 30 12 415 
Caldwell, 1992 (13)f 17 12 Cross-over 16.7 15 19 315 
*MTX dose given orally unless otherwise indicated. 
i-Study included a third triamcinolone arm, data from this arm was not included in the meta-analysis. 
$Unpublished study. 
than parallel studies. We also postulated that those trials 
which attempted a pretrial steroid tapering phase before 
randomizing patients into the trial might show a different 
magnitude of treatment effect, since these patients would be 
entering into the trial while already receiving the lowest 
steroid dose needed to control their asthma. Finally, we 
sought to do a subgroup analysis to determine whether 
trials which enrolled patients taking higher doses of pred- 
nisone (2 20 mg day- ‘), showed similar results to those 
trials in which patient’s baseline corticosteroid doses were 
lower. 
Results 
One hundred and thirty-five potentially relevant studies 
were identified and screened for retrieval. Ninety-three 
studies were excluded as not being clinical trials. Forty-one 
studies were retrieved for more detailed evaluation. Twenty 
of the 41 studies retrieved were excluded since they were 
review articles, or abstracts of studies later published as full 
papers. The 21 remaining studies, 20 in English, one in 
French, were independently reviewed by two reviewers. 
Nine studies were rejected by both reviewers since they were 
non-randomized, uncontrolled studies (3,16-23). Twelve 
studies were independently selected by both reviewers as 
being randomized, placebo-controlled trials suitable for 
inclusion in the meta-analyses (4-15). One of these studies 
was published only in abstract form, however, a copy of the 
unpublished manuscript was obtained directly from the 
investigators (13). The two reviewers independently agreed 
on the studies to be included and excluded in 100% of cases. 
Table 1 contains summary information concerning the 12 
included trials and an assessment of each trial’s quality 
score. There was agreement between the two reviewer’s 
quality scores for 11112 trials, with the weighted kappa 
statistic being 0.92. 
Of 12 trials, 11 reported FEV, measurements; one trial 
(9), measured peak expiratory flows rather than FEV,, and 
this trial was not included in the calculation of the weighted 
mean difference. The effect of methotrexate vs placebo on 
FEV, measurements is shown in Fig. 1. Compared to 
placebo, the use of methotrexate was associated with a 
pooled 6.0% improvement in FEV, over the course of the 
trial (95% CI, 1.0-l 1 .O%). 
All 12 trials analysed reduction in oral steroid dose as a 
primary endpoint. Figure 2 displays the data concerning 
steroid-sparing effects of methotrexate vs placebo for each 
trial and the pooled estimate across all trials. Compared 
to placebo, methotrexate was associated with an 18.2% 
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FIG. 1. Percent change in FEV,: methotrexate vs placebo. 
Values expressed as weighted mean difference with 95% 
confidence intervals. 
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FIG. 3. Mean steroid-sparing effect of methotrexate with 
95% confidence intervals, pooled analysis, overall and by 
subgroup. 
reduction in oral steroid use (95% CI, 11.7724.7%). The 
Cochran Q-test for statistical heterogeneity was of border- 
line significance (P=O.O6), therefore we decided to perform 
sensitivity analyses which had been generated a priori. 
Results from the parallel studies (n= 111) were analysed 
separately to determine if the estimate was affected by trial 
design. The pooled estimate for parallel studies revealed a 
19.6% reduction in oral steroid use (95% CI, 9.6-29.6%) 
and was similar to the overall pooled estimate for all the 
trials (Fig. 3). 
Two subgroups analyses were performed. Studies which 
employed a pretrial steroid tapering phase were analysed 
separately. Pooled results from the five trials which used 
this strategy shoyed a 24.6% reduction in oral steroid use 
(95% CI, 15&33:6%). A similar subgroup analysis was 
done using only those trials whose patients were taking an 
average of at least 20 mg day ~ ’ of prednisone before entry 
into the study. These, five trials (n=83) showed a pooled 
14.6% reduction in oral steroid dose (95% CI, 5623.6%) 
(Fig. 3). 
For six studies in which individual patient data were 
available we determined the likelihood of an individual 
patient achieving a 20% or greater reduction in oral steroid 
dose. The pooled odds ratio was 2.36 for methotrexate 
compared to placebo (95% CI, 1.25448%). 
WITHDRAWALS 
The 12 trials enrolled 250 patients of which there were 15 
patient withdrawals from the placebo arm and 14 with- 
drawals from the methotrexate arm. Eleven of the 14 
methotrexate-arm withdrawals occurred due to side effects 
of the therapy (five had gastrointestinal intolerance, four 
developed liver function test abnormalities, two developed 
pneumonia). Two withdrawals from the methotrexate arm, 
and three from the placebo arm, were due to severe 
uncontrolled asthma. 
ADVERSE EFFECTS ASSOCIATED WITH 
METHOTREXATE 
Eleven of the 12 trials reported on adverse effects. Minor 
gastrointestinal symptoms (nausea, vomiting, abdominal 
pain and diarrhoea) occurred more often in those patients 
taking methotrexate (45%) vs placebo (31%) k2=6.79, 
P=O.Ol). Similarly, increases in liver function tests occurred 
in more patients on methotrexate (21.4%) than in those on 
placebo (1.3%) (J2=30.4, P<O.OOl). There were no signifi- 
cant differences in rates of infection or stomatitis, which 
occurred infrequently in both groups. Bone marrow sup- 
pression and methotrexate pneumonitis were not observed. 
Three potentially life-threatening side-effects (two pneu- 
monias and one case of liver dysfunction) occurred in 159 
patients randomized to methotrexate vs none in those on 
placebo. Both cases of pneumonia occurred in patients 
who were enrolled in the study which used a higher dose 
of methotrexate, 30 mg week - ’ instead of 15 mg week ~ ’ 
(12). There were no deaths reported in any of the study 
patients. 
Discussion 
Compared to placebo, the addition of methotrexate allowed 
an 18% (3.3 mg of prednisone day - ‘) reduction in patients’ 
use of oral corticosteroids. 
Trials which enrolled patients taking higher doses of oral 
steroids ( 2 20 mg day - ’ of prednisone) did not show a 
greater steroid-sparing effect of methotrexate than those 
trials with patients on lower baseline doses of steroid. This 
finding is disappointing, since patients on high doses of oral 
corticosteroids are most likely to develop steroid-induced 
adverse effects, and they represent the patient population 
who would most benefit from an effective steroid-sparing 
medication. 
Seven of the 12 trials included in this meta-analysis 
(4,5,7-9,13,15) were able to achieve a 2 15% reduction in 
the oral steroid requirements of placebo-treated patients. 
The largest reported placebo effect was a dose reduction of 
39.6% (5). This suggests that intensive follow-up and moni- 
toring of these patients improved asthma control, or that 
some of the patients entering into the trials were on more 
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oral steroid than was actually needed to control their 
asthma. 
It is also somewhat disturbing that some patients enrolled 
in these trials had not been receiving high-dose inhaled 
steroids when they were enrolled into these steroid-sparing 
trials. Most of the trials only included patients if they 
were taking at least 800 pug day - ’ of beclomethasone or 
its equivalent (7-12,14,15), however, several of the trials 
(4,5,13) simply required that the patient had undergone ‘a 
previous adequate trial of inhaled steroid’. Some patients in 
these trials were therefore not receiving inhaled steroids at 
all at trial entry. The implication of this is that some of 
these patients may not have been oral steroid dependent if 
they had been on high-dose inhaled steroids and should 
therefore not have been entered into a steroid-sparing trial. 
The steroid-sparing effect of methotrexate was accom- 
plished without deterioration in the patient’s status, as 
evidenced by a pooled 6% improvement in FEV, for those 
on methotrexate vs those on placebo. All the trials included 
in this meta-analysis progressively tapered the study partici- 
pant’s oral steroid dose according to the status of their 
asthma, therefore it is not surprising that the FEV, was 
similar between the methotrexate and placebo groups at the 
end of the trials. 
Minor gastrointestinal complications and transient 
increases in liver enzymes were more common in patients 
randomized to methotrexate. The two cases of pneumonia 
occurred in patients enrolled in a study which caused a 
relatively high dose of methotrexate, 30 mg week ~ ‘, rather 
than the standard dose of 15 mg week ~ ’ used in the other 
11 studies. Although no deaths were reported during the 
double-blind study period, one study reported a death from 
Pneumocystis carinii pneumonia in a patient who was still 
taking methotrexate and prednisone several months after 
the study had ended (5). Similar sporadic reports exist in 
the literature of deaths of patients with asthma who were 
taking methotrexate and developed fatal methotrexate 
pneumonitis or infections (29-32). 
Meta-analysis is a powerful statistical tool for pooling 
data from several sources. By synthesizing available 
scientific evidence, a meta-analysis can provide empirical 
answers to scientific research questions. However, one 
potential weakness of any meta-analysis is publication bias. 
Theoretically, for our meta-analysis, publication bias could 
have led to an overestimation of the steroid-sparing effects 
of methotrexate, because reports of trials with negative 
results may have been less likely to be published. However, 
six of the 12 trials included in this analysis reported 
negative results -either a CI that included 1 or a P value 
greater than 0.05. Furthermore, our literature search ident- 
ified only one abstract that was not subsequently published 
as a full article, and this unpublished article was included in 
the meta-analysis. A funnel plot of the effect size of the 
studies plotted against sample size was constructed to assess 
for publication bias (Fig. 4). There was no evidence for 
publication bias: the plot reveals a wide dispersion of results 
among studies of small sample size and a narrower range of 
study results for larger studies. 
Although this meta-analysis indicates. that methotrcxate 
allows a reduction in oral steroid use that is statistically 
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FIG. 4. Assessment of potential publication bias: funnel 
plot of treatment effect vs study sample size. 
significant, it is unclear whether the magnitude of the 
observed steroid-sparing effect of methotrexate is clinically 
significant. The mean baseline dose of prednisone for all the 
patients entering into the 12 trials was 17.9 mg day- ‘; 
adding methotrexate allowed an average 3.3 mg day - ’ 
reduction in patients’ steroid dose over placebo. If we 
assume that 17.9 mg day ~ ’ of prednisone achieves asthma 
control equivalent to 14.6 mg day ~ ’ of prednisone plus 
15mgweekk’ of methotrexate, then choosing between 
these two treatment options depends on costs, convenience, 
and adverse effects. 
The actual drug acquisition costs for methotrexate are 
higher than for prednisone. The annual cost, in the 
Province of Ontario, of 15 mg week ~ ’ of methotrexate is 
$227.76 vs $6.72 for 5 mg day ~ ’ of prednisone. Methotrex- 
ate also requires monthly blood work, thus adding to costs 
and inconvenience for the patient. Patients on methotrexate 
experience significantly more minor gastrointestinal com- 
plaints and liver enzyme changes, and these. adverse effects 
can be expected to further increase medical costs and 
patient inconvenience. Finally, it is unclear whether an 
average 3.3 mg day - ’ reduction in oral corticosteroid use 
will help to prevent steroid-related adverse effects. For 
instance, studies of glucocorticoid-induced osteoporosis 
have shown that significant bone loss occurs even in 
patients taking less than 10 mg day - ’ of prednisone when 
compared to controls (33) and it is not currently known 
whether there is a threshold dose of glucocorticoid below 
which bone loss does not occur (34). The benefits of an 18% 
steroid-reducing effect of methotrexate are therefore 
unclear, since it is not possible to determine u priori in 
which patients this degree of steroid dose reduction can be 
expected to significantly retard bone loss. The issue is 
further complicated by recent reports which suggest that 
methotrexate itself, can cause osteopathy and osteoblast 
inhibition, even at low doses (35,36). 
Shortly after completion of our meta-analysis, a similar 
meta-analysis examining the effects of methotrexate in 
steroid-dependent asthma was published by Marin (37). 
This meta-analysis found that methotrexate allowed a 
23.7% (4.3 mg day ~ ‘) reduction in prednisone dose, and 
IO64 S. D. AARON ET AL. 
the author concluded that ‘low-dose methotrexate has 
a significant steroid-sparing effect in steroid-dependent 
asthmatic patients’. 
While results of Marin’s meta-analysis are somewhat 
similar to ours, we feel that our meta-analysis is a more 
rigorous study. We contacted authors of the original studies 
to retrieve additional data, and we obtained results from an 
additional unpublished paper which was not included in 
Marin’s analysis. We had two different reviewers select 
studies and abstract data from each study so as to improve 
the reliability and validity of our findings. We also did a 
meta-analysis of side-effects, something not done in Marin’s 
study. Based on the considerable side-effects in the meth- 
otrexate group documented in our meta-analysis, we were 
able to conclude that the very modest steroid-sparing 
benefits of methotrexate do not seem to outweigh its 
disadvantages. 
Our meta-analysis included an additional unpublished, 
negative study not analysed in Marin’s paper, and our 
estimate of the overall steroid sparing effect of methotrexate 
is therefore less than that found by Marin (3.3 mg pred- 
nisone spared day ~ i vs 4.3 mg prednisone day ~ ’ found in 
the Marin study). It is however, reassuring that the two 
results are somewhat similar, and certainly not discordant. 
This adds to the external validity of the results of both 
studies, since two independent meta-analyses were able to 
reach similar statistical results. 
In summary, we estimate that treating steroid-dependent 
asthmatics with low-dose methotrexate allows for a mean 
18% greater reduction in oral steroid requirements than 
placebo. Although methotrexate appears to have modest 
steroid-sparing effects, in absolute terms adding methotrex- 
ate only allowed a mean decrease in oral steroid dose of 
3.3 mg day ~ i greater than placebo. Furthermore, the ben- 
efits of methotrexate must be weighed against the potential 
complications of therapy, such as increased GI and hepatic 
side-effects, as well as the lack of clinical predictors for 
response. Given these results, it does not seem appropriate 
to recommend the use of methotrexate except for those 
asthmatics who are already experiencing substantial 
side-effects from corticosteroid therapy. 
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Appendix 
Let T, denote the estimate of the treatment effect in trial I, 
Ti=DTi - Dci, where DTi and DGi are the average percent 
changes in oral steroid dose between baseline and follow-up 
in the treatment and control groups, respectively. Let 6$ 
and 6oi2 be the variance of DTi and D+ respectively. The 
variance of any average percent change (i.e. either 6ri2 or 
6,,‘), was derived from the variances of the absolute mean 
prednisone doses at baseline and end of treatment. This 
variance calculation involved the following steps: (1) the 
percent change was converted to log-scale so that the 
variance calculation of the ratio of two random variables 
involved only the addition of the transformed variables. 
(2) Variance of a log-transformed variable was derived 
using the delta method and (3) a correlation of 0.8 was 
assumed for prednisone doses at baseline and end of 
treatment. 
An inverse-variance weighted estimate was used to com- 
bine the treatment effect T,s across i studies. The weighted 
estimate of the pooled treatment effect is 
JJTD’i> 
C(l/Vi) 
and the standard error of the pooled treatment effect is 
